Additionally, ongoing trials are evaluating Rintatolimod as a therapy for COVID-19 in cancer patients (NCT04379518) and post-COVID fatigue (NCT05592418), further expanding the clinical applications of this TLR3 agonist. This evidence concerns the gene TLR3 and cancer.